A Phase 1b Study to Evaluate TAK-659 in Combination With Nivolumab in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 04 Aug 2017
At a glance
- Drugs Nivolumab (Primary) ; TAK 659 (Primary)
- Indications Advanced breast cancer; Head and neck cancer; Non-small cell lung cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Takeda Oncology
- 28 Jul 2017 Planned number of patients changed from 120 to 126.
- 28 Jul 2017 Planned End Date changed from 31 Jul 2018 to 1 Jul 2019.
- 28 Jul 2017 Planned primary completion date changed from 1 Jul 2018 to 1 Jul 2019.